PATENT CLAIM ANALYSIS

Application Number: 15998475
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-04
Patent Classification: ["424", "093210"]

Abstract:
This invention relates to modified T cells that inducibly express a bioactive molecule, such as IL-7, and constitutively expresses an antigen receptor, such as a T cell receptor or chimeric antigen receptor that binds to a tumour antigen. The modified T cells may comprise a nucleic acid construct that comprises a first nucleotide sequence encoding the bioactive molecule, a second nucleotide sequence encoding the antigen receptor; an inducible promoter operably linked to the first nucleotide sequence and a constitutive promoter operably linked to the second nucleotide. Nucleic acid constructs and vectors are provided, as well as T cells comprising such constructs and vectors and therapeutic methods and uses thereof.

Claim (Index 39):
The method according to  claim 1  wherein the cancer is characterized by the presence of one or more cancer cells which bind to said antigen receptor.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 96.0
- Lexical Diversity: 2.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14375015', '14350588', '15949018', '15713464', '13266280']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7253880485366878
- 35 USC 102 Novelty (BERT): 0.5206316959746017
- Combined Prediction Score: 0.7049124132804792
- Mean Citation Score: 301.3585920000001
- Max Citation Score: 320.88467
- Similarity Product: 291.3823850023967

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test